Lutropin Alfa
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Lutropin alfa: From Ovulation Induction to Postural Orthostatic Tachycardia Syndrome
One-Sentence Summary
Lutropin alfa is a recombinant human luteinizing hormone (LH) used in assisted reproductive technology to trigger ovulation and support follicular steroidogenesis. The TxGNN model predicts it may be effective for postural orthostatic tachycardia syndrome (POTS), but this ranks 25,881st among all model predictions and is currently supported by no clinical trials and no published literature.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Ovulation induction / assisted reproductive technology (from known pharmacology — no formal indication text is available in this evidence pack) |
| Predicted New Indication | Postural orthostatic tachycardia syndrome (POTS) |
| TxGNN Prediction Score | 97.04% (model rank 25,881 of all candidate pairs) |
| Evidence Level | L5 |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for Lutropin alfa is not available in this evidence pack (flagged as a High-severity data gap). Based on known pharmacology, Lutropin alfa is a recombinant LH agonist that acts on ovarian and testicular LH receptors to stimulate ovulation and steroid hormone production — its established use is in fertility treatment, not in autonomic or cardiovascular disease.
POTS is a disorder of autonomic nervous system and cardiovascular regulation. There is no established mechanistic pathway linking LH receptor activation to the pathophysiology of POTS, and the evidence pack’s own repurposing rationale for this candidate explicitly states that no known biological connection exists. This suggests the high TxGNN score reflects a data-driven pattern in the knowledge graph rather than a plausible pharmacological mechanism, which is consistent with the very low model rank (25,881st) despite the seemingly high score.
Reviewing the other nine top-ranked candidates in this evidence pack (peptic esophagitis, trichotillomania, Raynaud disease, duodenal ulcer, Tourette syndrome, esophageal disease, sinoatrial block, multiple endocrine neoplasia, duodenogastric reflux) shows the same pattern: each rationale states no known mechanistic link to LH receptor signalling, and none is supported by clinical trials or literature specific to that indication. The one exception, multiple endocrine neoplasia, has a single Phase IV trial in the record (NCT01081626), but that trial studied gonadotropin use in ovulation induction generally and was graded “C” relevance — an incidental database co-occurrence, not evidence of efficacy in MEN.
Clinical Trial Evidence
Currently no related clinical trials registered for postural orthostatic tachycardia syndrome.
Literature Evidence
Currently no related literature available for postural orthostatic tachycardia syndrome.
Australia Market Information
Lutropin alfa is not currently marketed in Australia — there are no ARTG entries in this evidence pack, and no approved local indication text is available for reference.
Safety Considerations
Safety data (key warnings, contraindications, drug interactions) are not available in this evidence pack, and the local product label warnings/contraindications data is flagged as a Blocking data gap (DG001) — this must be resolved before any safety pre-assessment can proceed. As the product is not marketed in Australia, there is no TGA-approved Product Information to reference; overseas product labelling (e.g. for Luveris) would need to be sourced and reviewed.
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate is supported only by a TxGNN model score (L5 evidence) — there are no clinical trials or published literature for Lutropin alfa in POTS, the model’s own mechanistic rationale finds no biological link between LH receptor activity and autonomic/cardiovascular regulation, and the predicted pair ranks poorly (25,881st) among all model outputs despite the high raw score. The drug is also not currently marketed in Australia.
To proceed, the following is needed:
- Confirmed mechanism of action data (currently a data gap)
- TFDA/TGA-equivalent product label warnings and contraindications (currently a Blocking data gap — DG001)
- Independent pharmacological or preclinical rationale connecting LH signalling to POTS pathophysiology
- Any emerging clinical trial or case-report evidence specific to this indication
- If pursuing repurposing work on this drug more broadly, the multiple endocrine neoplasia candidate (L4, one incidentally-relevant trial) would need dedicated mechanistic and trial evidence before it could be considered stronger than Hold
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.